It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury: Toronto Wednesday, November 13, 2024, 1 ...

Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...

Pneumonia, frequently intertwined with cardiovascular disease, escalates the risk of heart complications like heart attacks ...

Scientists are hoping to find ways of turning back the clock on human hearts, allowing patients to grow new heart muscle.

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a ...

Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Suita, Japan Therapeutic hypothermia inhibits organ damage by suppressing metabolism, which makes ...

The Philadelphia 76ers are going to have to wait a little longer to see offseason acquisition Paul George in action. George missed Philadelphia's season-opening 124-109 loss to the Milwaukee Bucks ...

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research ... after the cardiac event. While the current focus is on heart repair after heart attacks, Deb's team is ...

More information: A Humanized Monoclonal Antibody Targeting an Ectonucleotidase Rescues Cardiac Metabolism and Heart Function after Myocardial Infarction, Cell Reports Medicine (2024). DOI: 10. ...

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a first-of-its-kind experimental therapy that has the potential to enhance ...

CULVER CITY, Calif., October 24, 2024--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial ...